7 High Growth Penny Stocks That Are Profitable in 2025

3. MannKind Corporation (NASDAQ:MNKD)

Price: $4.10

Year-Over-Year Sales Growth: 32.50%

TTM Net Income: $30.12M

Number of Hedge Fund Holders: 29

Analyst Upside Potential: 120.05%

MannKind Corporation (NASDAQ:MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC Capital’s analyst Douglas Miehm lowered the firm’s price target on MannKind Corporation (NASDAQ:MNKD) from $10 to $8, while maintaining a Buy rating on the stock.

The analyst believes the current stock price reflects an overly pessimistic view of MannKind Corporation (NASDAQ:MNKD)’s products, particularly the Tyvaso DPI royalties, and assigns no value to the company’s product pipeline. During the fiscal first quarter of 2025, the company noted that its Afrezza, an inhaled insulin, saw 20% new prescription growth and 14% total prescription growth year-over-year. Moreover, the insulin’s pediatric Phase 3 trial is progressing, and the company also met with the FDA’s plan file for its approval in mid-2025.

MannKind Corporation (NASDAQ:MNKD) develops and sells inhaled therapeutic products for diabetes and rare lung diseases.